FDA Approved Products

6,646 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
DDAVP
desmopressin acetate
LOE Approaching
Ferring Pharmaceuticals
NASAL · SOLUTION
primary nocturnal enuresis
1978
NDA
30/100
DDAVP
desmopressin acetate
LOE Approaching
Ferring Pharmaceuticals
ORAL · TABLET
primary nocturnal enuresis
1995
NDA
30/100
DDAVP
desmopressin acetate
LOE Approaching
Nordic Pharma
INJECTION · INJECTABLE
nephrogenic diabetes insipidusthere is evidence of an abnormal molecular form of factor VIII antigen+5
1984
NDA
30/100
DDAVP (NEEDS NO REFRIGERATION)
desmopressin acetate
LOE Approaching
Ferring Pharmaceuticals
NASAL · SPRAY, METERED
nephrogenic diabetes insipiduscentral diabetes insipidus
1978
NDA
30/100
DECA-DURABOLIN
nandrolone decanoate
LOE Approaching
INJECTION · INJECTABLE
the anemia of renal insufficiencyred cell mass+1
1962
NDA
30/100
DECABID
indecainide hydrochloride
LOE Approaching
Eli Lilly and Company
ORAL · TABLET, EXTENDED RELEASE
1989
NDA
30/100
DECADRON
dexamethasone sodium phosphate
LOE Approaching
Merck & Co.
OPHTHALMIC, OTIC · SOLUTION/DROPS
Rheumatoid arthritispsoriasis+6
1959
NDA
30/100
DECADRON
dexamethasone
LOE Approaching
Merck & Co.
ORAL · ELIXIR
Rheumatoid arthritispsoriasis+6
1960
NDA
30/100
DECADRON
dexamethasone sodium phosphate
LOE Approaching
Merck & Co.
TOPICAL · CREAM
Rheumatoid arthritispsoriasis+6
1959
NDA
30/100
DECADRON
dexamethasone sodium phosphate
LOE Approaching
Merck & Co.
OPHTHALMIC · OINTMENT
Rheumatoid arthritispsoriasis+6
1959
NDA
30/100
DECADRON
dexamethasone sodium phosphate
LOE Approaching
Merck & Co.
INJECTION · INJECTABLE
Rheumatoid arthritispsoriasis+6
1959
NDA
30/100
DECADRON
dexamethasone
LOE Approaching
Merck & Co.
ORAL · TABLET
Rheumatoid arthritispsoriasis+6
1958
NDA
30/100
DECADRON W/ XYLOCAINE
dexamethasone sodium phosphate; lidocaine hydrochloride
LOE Approaching
Merck & Co.
INJECTION · INJECTABLE
Rheumatoid arthritispsoriasis+9
1962
NDA
30/100
DECADRON-LA
dexamethasone acetate
LOE Approaching
Merck & Co.
INJECTION · INJECTABLE
1973
NDA
30/100
DECAPRYN
doxylamine succinate
LOE Approaching
Sanofi
ORAL · TABLET
cough due to minor throatbronchial irritation+3
1948
NDA
30/100
DECASPRAY
dexamethasone
LOE Approaching
Merck & Co.
TOPICAL · AEROSOL
dermatomyositispolymyositis+9
1961
NDA
30/100
DECITABINE
decitabine
Peak
Fosun Pharma
INTRAVENOUS · POWDER
untreatedde novo+10
2014
NDA
30/100
DECLOMYCIN
demeclocycline hydrochloride
LOE Approaching
Pfizer
ORAL · SYRUP
infections caused by the following gram-negative microorganismsbacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli+8
1960
NDA
30/100
DECLOMYCIN
demeclocycline hydrochloride
LOE Approaching
ORAL · TABLET
infections caused by the following gram-negative microorganismsbacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli+8
1964
NDA
30/100
DECLOMYCIN
demeclocycline hydrochloride
LOE Approaching
Pfizer
ORAL · CAPSULE
infections caused by the following gram-negative microorganismsbacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli+8
1960
NDA
30/100
DEHYDRATED ALCOHOL
dehydrated alcohol
Launch
INTRAVENOUS · SOLUTION
2025
NDA
30/100
DELATESTRYL
testosterone enanthate
LOE Approaching
INJECTION · INJECTABLE
1953
NDA
30/100
DELESTROGEN
estradiol valerate
LOE Approaching
Pfizer
INJECTION · INJECTABLE
the: 1
1954
NDA
30/100
DELFEN
nonoxynol-9
LOE Approaching
Personal Genomics
VAGINAL · AEROSOL
1963
NDA
30/100
← PreviousPage 46 of 277Next →